Department of Cardiology, Hangzhou Dingqiao's Hospital, Hangzhou, Zhejiang, China; Department of Cardiology, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Hangzhou Red Cross Hospital, Hangzhou, Zhejiang, China.
Clin Ther. 2019 Oct;41(10):2137-2152.e12. doi: 10.1016/j.clinthera.2019.08.008. Epub 2019 Sep 21.
The goal of this study was to investigate the effects of the antianginal drugs ranolazine, nicorandil, and ivabradine on coronary microvascular function.
Electronic scientific databases were searched for randomized trials investigating the effects of antianginal drugs on coronary microvascular function. Primary outcomes were changes in the coronary flow reserve (CFR), index of microvascular resistance (IMR), and myocardial perfusion reserve index (MPRI). The secondary outcome was the Seattle Angina Questionnaire scores. The standardized mean difference or weighted mean difference (WMD) (95% CI) served as a summary statistic.
The antianginal drugs ranolazine, nicorandil, and ivabradine did not increase the CFR compared with the control drugs (standardized mean difference, 0.39; 95% CI, -0.08 to 0.85; P = 0.10). Ranolazine did not increase the global MPRI compared with the control drugs (weighted mean difference [WMD], 0.11; 95% CI, -0.06 to 0.29; P = 0.21). However, in the subgroups with a baseline CFR <2.5 or a global MPRI <2, ranolazine increased the global MPRI (WMD, 0.19; 95% CI, 0.10 to 0.27; P < 0.0001). In addition, the subendocardial midventricular MPRI (mid-subendocardial MPRI) was improved after ranolazine treatment (WMD, 0.12; 95% CI, 0.03 to 0.20; P = 0.007). Moreover, nicorandil significantly reduced the IMR compared with the control drugs (WMD, -7.63; 95% CI, -11.82 to -3.44; P = 0.0004). In addition, ranolazine and ivabradine improved 3 of the 5 Seattle Angina Questionnaire scores.
Ranolazine improved the global MPRI in patients with definite coronary microvascular dysfunction and the mid-subendocardial MPRI with suspicious coronary microvascular dysfunction, and nicorandil reduced the IMR. In addition, ranolazine and ivabradine reduced angina. Moreover, it is possible that the IMR and mid-subendocardial MPRI are more sensitive than the CFR and global MPRI for evaluating coronary microvascular function.
本研究旨在探讨抗心绞痛药物雷诺嗪、尼克地尔和伊伐布雷定对冠状动脉微血管功能的影响。
电子科学数据库检索了评估抗心绞痛药物对冠状动脉微血管功能影响的随机试验。主要结局是冠状动脉血流储备(CFR)、微血管阻力指数(IMR)和心肌灌注储备指数(MPRI)的变化。次要结局是西雅图心绞痛问卷评分。标准化均数差或加权均数差(WMD)(95%CI)作为汇总统计量。
与对照药物相比,抗心绞痛药物雷诺嗪、尼克地尔和伊伐布雷定并未增加 CFR(标准化均数差,0.39;95%CI,-0.08 至 0.85;P=0.10)。雷诺嗪与对照药物相比并未增加整体 MPRI(WMD,0.11;95%CI,-0.06 至 0.29;P=0.21)。然而,在 CFR<2.5 或整体 MPRI<2 的亚组中,雷诺嗪增加了整体 MPRI(WMD,0.19;95%CI,0.10 至 0.27;P<0.0001)。此外,雷诺嗪治疗后心内膜下中层心肌 MPRI(心内膜下中层 MPRI)得到改善(WMD,0.12;95%CI,0.03 至 0.20;P=0.007)。此外,与对照药物相比,尼克地尔显著降低了 IMR(WMD,-7.63;95%CI,-11.82 至-3.44;P=0.0004)。此外,雷诺嗪和伊伐布雷定改善了西雅图心绞痛问卷 5 项评分中的 3 项。
雷诺嗪改善了明确冠状动脉微血管功能障碍患者的整体 MPRI 和可疑冠状动脉微血管功能障碍患者的心内膜下中层 MPRI,尼克地尔降低了 IMR。此外,雷诺嗪和伊伐布雷定减轻了心绞痛。此外,IMR 和心内膜下中层 MPRI 可能比 CFR 和整体 MPRI 更能敏感地评估冠状动脉微血管功能。